DailyIQ
|
Sector:HealthcareAll sectors
Last updated 4 minutes ago

GEHC·GE HealthCare Technologies Inc.

$.
+. (+.%)
After Hours
High
$63.82
Open
$61.91
Market Cap
28.05B
52W High
$89.77
Low
$60.65
P. Close
$63.21
P/E
14.69
52W Low
$58.75
Fwd P/E
11.79
DailyIQ Est.
$81.59
Technical Score (1D)
32
SELL
News Sentiment
78
BULLISH
A sharp rise in open interest and implied volatility in GE HealthCare options signals that traders are positioning for a notable price move. The spike suggests market participants expect either an earnings surprise or a regulatory announcement that could materially affect the company’s valuation. Because options pricing incorporates forward‑looking expectations, the elevated implied volatility is a leading indicator of potential upside or downside risk in the near term. In the next 1–10 trading days, this heightened options activity could translate into tighter bid‑ask spreads and increased price swings as the market digests any forthcoming news. The upcoming earnings release, scheduled for next week, is a key event that could confirm or refute the expectations embedded in the options market. Additionally, any pending regulatory filings or approvals related to GE HealthCare’s product pipeline could trigger the anticipated move. Traders should monitor the implied volatility curve for signs of steepening or flattening, which would indicate shifting sentiment about the magnitude of the expected event. Watching the volume of new options contracts versus expirations will help gauge whether the market is hedging or speculating on the outcome. Finally, keep an eye on any press releases or analyst updates that could provide concrete information about earnings or regulatory developments, as these will be the catalysts that move the stock.
Earnings Summary
GE HealthCare Technologies Inc. is a global leader in medical technology, offering diagnostic imaging, patient monitoring, and pharmaceutical diagnostics across advanced imaging systems, ultrasound, and monitoring equipment, positioning it within the competitive medical devices sector. In the most recent reporting cycle, Q4 2024 saw EPS of $1.45 versus an estimate of $1.26 and revenue of $5.319 billion, while Q1 2025 posted EPS of $1.01 against an estimate of $0.91 and revenue of $4.778 billion; the following quarter, Q2 2025, delivered EPS of $1.06 versus $0.92 and revenue of $5.007 billion, and Q3 2025 produced EPS of $1.07 versus $1.05 and revenue of $5.143 billion, indicating a steady EPS beat trend and modest revenue acceleration; however, Q4 2025 revenue of $5.698 billion fell slightly below the $5.723 billion estimate and EPS of $1.44 beat the $1.43 estimate, while Q1 2026 revenue rose to $5.131 billion but EPS of $0.99 missed the $1.05 estimate, suggesting a recent deceleration in profitability and a potential shift in cost dynamics. Historically, GEHC has maintained a YoY revenue growth trajectory from Q4 2024 to Q4 2025, with EPS consistently beating analyst expectations in five of the last six quarters, underscoring a pattern of earnings resilience even as revenue growth moderates; the company’s guidance has remained cautious, reflecting competitive pressures in imaging. Recent market sentiment, highlighted by a sharp rise in options implied volatility and BTIG’s price target cut to $75, signals heightened expectations for an earnings surprise or regulatory announcement that could materially affect valuation, while the downgrade reflects concerns over margin compression amid intensified competition. Investors should watch for the Q2 2026 earnings release, particularly EPS and revenue guidance, as well as any updates on capital allocation, product pipeline acceleration, or cost‑cutting initiatives that could mitigate margin pressure and restore upside potential.

EPS

EstBeatMiss
$0.83$1.01$1.18$1.35$1.52Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$1.03 - -
Q1'26$1.05$0.99-5.7%
Q4'25$1.43$1.44+1.0%
Q3'25$1.05$1.07+2.2%
Q2'25$0.92$1.06+15.4%
Q1'25$0.91$1.01+10.6%

Revenue

EstBeatMiss
$4.6B$4.9B$5.3B$5.6B$5.9BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$5.4B - -
Q1'26$5.0B$5.1B+2.1%
Q4'25$5.7B$5.7B-0.4%
Q3'25 - $5.1B -
Q2'25 - $5.0B -
Q1'25 - $4.8B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

GEHC Stock Snapshot

GEHC is currently trading at $63.38, giving GE HealthCare Technologies Inc. a market cap of 28.05B and a P/E ratio of 14.7. Today's range spans $60.65–$63.82, with shares opening at $61.91 and moving up $0.17 (0.3%) from the prior close. DailyIQ's technical score sits at 32/100 (SELL) with a news sentiment reading of 78/100.

Over the past year GEHC has traded between $58.75 and $89.77 - the current price is +7.9% off the 52-week low and -29.4% from the high. 30 analysts cover the stock with a Buy consensus and a mean 12-month target of $78.95 (range $65.00–$98.00), implying upside of +24.6%.

Earnings estimate risk is at the forefront for GE HealthCare Technologies Inc. (GEHC) - a large-cap Healthcare name (28.05B market cap) showing a SELL (32/100) alongside bullish sentiment (78/100) often flags a period where consensus estimates are still catching down to what the market is already pricing in. Price: $63.38 (near 52-week lows in $58.75–$89.77). (P/E: 14.7) Active managers who track the technical-fundamental gap tend to position ahead of the revision, not after it.

Analyst coverage for GEHC becomes a double-edged factor in a SELL phase: at 28.05B in Healthcare market cap, active coverage is high enough that downgrade risk is real and impactful. The 32/100 technical reading and bullish sentiment (78/100) at $63.38 (near 52-week lows) place the stock in the zone where one or two high-profile estimate cuts can convert a grinding decline into a sharper re-rating — the $58.75–$89.77 range establishes where that repricing lands.